FDA Grants Priority Review to Pacritinib for Treating Myelofibrosis With Severe Thrombocytopenia

Retrieved on: 2021-06-02 14:03:45

Tags for this article:

Click the tags to see associated articles and topics

FDA Grants Priority Review to Pacritinib for Treating Myelofibrosis With Severe Thrombocytopenia. View article details on hiswai:

Excerpt

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis. News release.

Article found on: www.cancernetwork.com